Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AssigneeIdera Pharmaceuticals, Inc.
InventorsEkambar Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
Life of this patent
Estimating the term…
Abstract
The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
Claims30
1-25. (canceled)
A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.
A method for therapeutically treating a patient having disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.
A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.
A method for treating an autoimmune disorder, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.
A method for treating airway inflammation or allergy, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.
A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
A method for therapeutically treating a patient having disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
A method for treating an autoimmune disorder, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
The method according to claim 51, wherein such conjugation is to the 3′-end of the oligonucleotide compound.
A method for treating airway inflammation or allergy, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
Dependencies are inferred from the claim text.